Insider filing · NVCT

Marlio Charles Mosseri bought $1.2M of Nuvectis Pharma (NVCT)

Executed Feb 7 2025, disclosed Feb 11 2025, 4 days later.

Over the 21 trading sessions from the disclosed entry session (Feb 11 2025), the stock returned +26.5% (delay-adjusted); from the execution session (Feb 7 2025), +5.1%. Derived: entry at the session's open, exit at the close 20 sessions later.

MM Marlio Charles Mosseri 10% owner profile →

Marlio Charles Mosseri (10% owner) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales, 1 filed past the two-business-day deadline), most often in Nuvectis Pharma, Inc. (NVCT). Across 2 priced purchase filings, the average 21-session return was -0.0% from execution and +6.0% from disclosure (delay-adjusted; derived). The largest single filing was $957K of NVCT (154,770 sh across 3 lots, as filed), executed Oct 23 2025.

NVCT Nuvectis Pharma, Inc. NVCT · Healthcare · 7 filings in 24 months ticker →

Healthcare · Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of s…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→